BETA: Please send your feedback!
Amgen
AMGN:NAS
Biotechnology
$0
MEGA cap
$219.19
(10.41%)
-0.05%
since start of 2020
16.93
About
Biotechnology
Founded 1980
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. Its products include aranesp, blincyto, corlanor, enbrel, epogen, imlygic, kyprolis, neulasta, neupogen, nplate, parsab, prolia, repatha, sensipar, vectibix, and xgeva. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Joseph Rubinfeld, PhD | Founder | Male |
| Pitch Johnson, Jr., MBA | Founder | Male |
| Jonathan P. Graham | Secretary, Senior Vice President & General Counsel | Male |
| Lori A. Johnston | Senior Vice President-Human Resources | Female |
| Bill Bowes, Jr., MBA | Founder | Male |
| George B. Rathmann, PhD | Founder | Male |
| Leroy E. Hood, MD, PhD | Founder | Male |
| Robert A. Bradway, MBA | Chairman & Chief Executive Officer | Male |
| Arvind K. Sood | Investor Relations Contact | Male |
| David W. Meline, MBA | Chief Financial Officer & Executive Vice President | Male |
| Steven K. Galson, MD | Senior VP-Global Regulatory Affairs & Safety | Male |
| Sean E. Harper, PhD | Executive Vice President-Research & Development | Male |
| Victoria H. Blatter | Senior Vice President-US Government Affairs | Female |
| Paul R. Eisenberg, MD | Chief Medical Officer & Senior VP-Global Medical | Male |
| Esteban Santos | Executive Vice President-Operations | Male |
Mindful Investing Summary
Amgen - Competitors and Related Companies
How Amgen stacks up to its peers in the Biotechnology industry or with competing business segments.
Amgen
AMGN:NAS
Biotechnology
$0
MEGA cap
$219.19
(10.41%)
-0.05%
since start of 2020
16.93
Biogen
BIIB:NAS
Biotechnology
$55.17bn
MEGA cap
$316.95
(15.74%)
0.11%
since start of 2020
10.06
Celgene
CELG:NAS
Biotechnology
$0
MEGA cap
$108.24
(0.00%)
0%
since start of 2020
—
Gilead Sciences
GILD:NAS
Biotechnology
$94.41bn
MEGA cap
$74.99
(0.32%)
0.15%
since start of 2020
17.69
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
$377.68bn
MEGA cap
$143.26
(5.78%)
0.02%
since start of 2020
25.08
Alexion Pharmaceuticals
ALXN:NAS
Biotechnology
$21.89bn
LARGE cap
$98.56
(3.84%)
-0.06%
since start of 2020
9.14